Author

Leah J. Hogdal

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Ahmed M. MamdouhiD· 1 shared Anthony G. LetaiiD· 1 shared Daniel Tan En Liang· 1 shared Elyse A. OlesinskiiD· 1 shared Fang Qi Lim· 1 shared Koji ItahanaiD· 1 shared Nicole Si En Lin· 1 shared Nishtha Chitkara· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahmed M. MamdouhORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade

Ahmed M. Mamdouh, Elyse A. Olesinski, Fang Qi Lim, Shaista Shabbir Jasdanwala, Yang Mi, Nicole Si En Lin, Daniel Tan En Liang, Nishtha Chitkara, Leah J. Hogdal, Robert Coleman Lindsley, Anthony G. Letai, Koji Itahana, Shruti Bhatt

This study identifies that TP53 mutations in AML lead to resistance to VenAza therapy by blocking caspase-3/7 activation after mitochondrial outer membrane permeabilization.

bioRxiv · Aug 28, 2025 · PreprintCancer Biology